Return to Results

Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF)

new search

Trial Conditions
  • Heart Failure
What is the purpose of this trial?

This study is being performed to determine if the drug that is being researched, Nesiritide (Natrecor), as compared to placebo, plus the usual treatment for acute decompensated heart failure (standard of care) helps improve breathing, reduce hospital readmissions, and helps patients live longer. Description: Regardless of which group patients are randomized to, all patients will receive the usual treatment for acute decompensated heart failure (standard of care), in addition to the study drug. The study drug will be given intravenously for up to 7 days, and will be adjusted according to the patient’s condition. During the infusion, the patient will be assessed frequently, and this may include daily blood work, a physical exam, frequent blood pressure measurements, pulse rate, respiratory rate, weight measurement, urine sampling and questioning about symptoms and breathing. Most or all of these assessments will be repeated after discharge on day 30, in the clinic, and by phone 6 months following discharge.

Date & Status



 Patients with heart failure will be considered for the trial.

Steward Physician(s)
  • St. Elizabeth's Medical Center - Recruiting
For more information about this trial, contact

Ann M. Pieczek, BSN, RN
Phone: 617-789-3043

Physician Researcher

Physician Name/s:

  • James P. Morgan MD
  • Lana  Tsao MD
  • Other Information

    Sponsor: Scios, Inc.
    Phase: Phase 4
    Trial ID: 00413
    Volunteers:  Not Accepting Healthy Volunteers

    new search

    Connect with Steward

    Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

    Subscribe to our patient e-newsletter

    Copyright © 2015 Steward Health Care
    Connect Healthcare Panacea CMS Solutions